[Skip to Navigation]
December 1978

Gastrointestinal Therapeutic System for Acetazolamide: Efficacy and Side Effects

Author Affiliations

From ALZA Research, Palo Alto, Calif. Dr Bayne is now with Cooper Laboratories, Mountain View, Calif.

Arch Ophthalmol. 1978;96(12):2219-2221. doi:10.1001/archopht.1978.03910060521010

• Acetazolamide has been formulated in a new gastrointestinal therapeutic system that delivers the drug at an essentially constant rate of 15 mg/hr (GITS 15/125). We compared the therapeutic effect, magnitude of plasma concentration fluctuations, and incidence of side effects produced by the GITS 15/125 with conventional 250-mg acetazolamide tablets on eight glaucomatous patients randomly assigned to a different regimen each week.

One or two GITS 15/125 twice a day (bid) were found as effective in reducing intraocular pressure as one 250-mg acetazolamide tablet. Plasma concentration fluctuations with the GITS 15/125 were decreased, compared with acetazolamide tablets, and, as a result, the incidence of drowsiness, tingling feet, tingling hands, and confusion was substantially reduced.

Add or change institution